Self-contained format
Powder and solvent are presented together in one bottle.
The lead asset
Coxor® 300 mg
Asamedic’s lead pharmaceutical asset: a 300 mg acetylsalicylic acid powder and solvent for oral solution.
Product overview
A differentiated asset for the emergency-care pathway.
Coxor® is a powder and solvent for oral solution containing 300 mg acetylsalicylic acid.
For the approved indication, directions for use, contraindications and other safety information, always consult the approved product information. Consumer information is available at coxor.no, and the Norwegian product entry is available through Felleskatalogen.
Coxor® 300 mgPowder and solvent for oral solution.What makes it different
Formulation development
Development work has examined the absorption profile of Coxor® compared with conventional ASA formats.
Regulatory foundation
The product was approved through a European DCP and launched in Norway in 2023.
Development and evidence
A formulation story grounded in pharmaceutical development.
Peer-reviewed publication
A study of Coxor® was published in a peer-reviewed journal. The publication reports the study findings and methods.
Read the publicationRegulatory approval
European DCP approval was completed in 2021 with Norway as RMS and Denmark as CMS.
Patent position
Coxor® is protected by patents in multiple jurisdictions, supporting long-term commercial defensibility.
For healthcare professionals
Access professional product information.
Clinical, regulatory and product information should be reviewed in the appropriate professional context.
View science & evidence